Surfactant therapy for meconium aspiration syndrome in Dr. Soetomo General Hospital – A case series

Introduction: Meconium staining of amniotic fluid (MSAF) is a natural phenomenon in pregnant mothers and their fetuses. MSAF may lead to developing Aspiration Syndrome (MAS). Surfactant replacement therapy has recently emerged as MAS, but no guideline outlines how administer it properly. Case Presentation: We present two term neonates with severe MAS cases focusing on the bolus surfactant therapy. The first baby was given at 23 hours after birth second 8 birth. used Survanta (beractant) dose 100 mg/kg BW both cases. Clinical improvement observed 24 administration different clinical characteristics, treatment approaches, outcomes.Conclusion: In conclusion, therapeutic improve outcomes without significant adverse side effects.